The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp1053
BENCH TO BEDSIDE TRANSLATION AND TARGETED THERAPEUTIC INTERVENTIONS IN EOE
Date
May 9, 2023
Explore related products in the following collection:
This session will feature speakers who will examine the mechanisms of inflammation and epithelial tissue remodeling during eosinophilic esophagitis (EoE). Epithelial cell and immune cell biology will be discussed. Biologics currently used for targeted therapeutic interventions in EoE will be considered.
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…